Program
DONQ52
A development code.
In Hoffmann-La Roche's pipeline, anti-HLA-DQ2.5 x gluten peptides
. Its studies are mostly in Celiac Disease, led by Hoffmann-La Roche.
Furthest: phase 2, since Nov 16, 20252 company-led studies, 1 open or runningNext primary completion: Jun 15, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 21 open or running | phase 2since Nov 16, 2025 | Jun 13, 2022 | Jun 15, 2027phase 2 · NCT07239336 |
- Named in Hoffmann-La Roche’s own pipeline as
CHU anti-HLA-DQ2.5 x gluten peptides
, phase 2, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2022First study: phase 1 study in Celiac DiseaseFirst studyNCT05425446 · 56 enrolled · United States, Australia
- Nov 16, 2025Phase 2 study in Celiac DiseasePhase 2 reachedNCT07239336 · 92 planned · United States, Australia, New Zealand
Ahead
- Jun 15, 2027Primary completion: phase 2 study in Celiac DiseaseNCT07239336
TargetBeta
“anti-HLA-DQ2.5 x gluten peptides”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07239336Celiac Disease · United States, Australia, New Zealand | 2 | Recruiting | Jun 15, 2027 | 92 |
| NCT05425446Celiac Disease · United States, Australia | 1 | Completed | Aug 9, 2024 | 56 |
How it is read
Names in the registry
- “DONQ52”, 2 entries
Codes read as this program: DONQ52.
Conditions, from the studies’ own filings
- Celiac Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.